OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase I/II Study of its Antibody-Drug Conjugate (ADC) targeted cancer therapy, OBI-999

Date of occurrence of the event: Aug 31, 2019 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head Office Reciprocal shareholding ratios: Not applicable Cause of occurrence: FDA clearance of IND Phase I/II Study Application of Globo-H Antibody-Drug Conjugate, OBI-999. Countermeasures: None Any other matters that need to […]

This article is password protected.

To view the content, please enter your password in the field below